PMG
ALNY icon

ProVise Management Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

ProVise Management Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,598
Closed -$261K – 329
2022
Q1 		$261K Sell
1,598
-30
-2% -$4.57K 0.02% 309
2021
Q4 		$276K Buy
1,628
+30
+2% +$5.58K 0.03% 315
2021
Q3 		$302K Hold
1,598
– – 0.03% 287
2021
Q2 		$271K Hold
1,598
– – 0.03% 316
2021
Q1 		$226K Buy
+1,598
New +$240K 0.02% 316

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ProVise Management Group's ALNY Position: Q2 2022 in Review

ProVise Management Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 1,598 shares — an estimated $261K sold.

ProVise Management Group first reported a position in ALNY in Q1 2021 and held it in 5 quarters. The position peaked at $302K in Q3 2021. 423 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

  • ProVise Management Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • ProVise Management Group sold 1,598 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $261K.
  • ProVise Management Group first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • ProVise Management Group's Alnylam Pharmaceuticals position peaked at $302K in Q3 2021.
  • 423 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on ProVise Management Group's 13F filing for Q2 2022, filed 8 Aug 2022.